RT Journal Article
SR Electronic
T1 Clinical Characteristics of Patients With Prolonged Disease-Free Survival After Primary Treatment in Advanced Ovarian Cancer: A Brief Report
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 475
OP 477
DO 10.1097/IGC.0b013e31820bf251
VO 21
IS 3
A1 Michael R. Milam
A1 Robyn Harrell
A1 Roland Bassett
A1 Lynn P. Parker
A1 Daniel S. Metzinger
A1 Pedro T. Ramirez
YR 2011
UL http://ijgc.bmj.com/content/21/3/475.abstract
AB Objective Optimal cytoreduction and response to chemotherapy have been associated with prolonged disease-free survival (DFS), but there are limited data regarding the clinical characteristics of those patients with optimal 5-year DFS (5YrDFS) outcomes.Methods A case-control study was performed on 32 patients who were progression-free and alive at 5 years with advanced ovarian cancer 5YrDFS from 1993 to 2005 for this institutional review board-approved study. Matching controls were identified from the subset of patients who died or experienced disease progression before 5 years.Results One hundred sixty patients were evaluated. There was no statistical difference between cases and controls in regard to neoadjuvant chemotherapy, grade, race, preoperative cancer antigen-125 level, optimal cytoreduction, operating room time, length of hospital stay, or total chemotherapy cycles in regard to 5YrDFS. If a patient achieved complete response after primary treatment, the likelihood of progression-free survival 5 years or longer is 7 times more likely, (odds ratio = 7.2 [95% confidence interval = 2.3-22.4]; P = 0.0006).Conclusion In this matched case-control analysis, complete response after primary treatment was the only significant factor associated with 5YrDFS. Further study is needed in patient and tumor characteristics to identify those patients who may have poor or favorable outcomes before treatment completion.